Skip to content

03759.HK

Pharmaron Beijing Co., Ltd.

HKSE · Healthcare · Biotechnology · CN

HKD 26.98
+0.22%
Ask drillr

Year over year

Reported trailing growth

Revenue
+17.9%
EBITDA
+16.4%
EBIT
+24.2%
EPS
+16.5%
Free cash flow
—
Operating cash flow
-15.9%

Forward estimates

Based on analyst estimates

Revenue
+15.0%
EBITDA
+112.4%
EPS
+67.5%

Three-year CAGR

Revenue
+11.1%
EBITDA
+9.1%
EBIT
+4.5%
Net income
+6.6%
EPS
+1.5%
Free cash flow
+3.0%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026